A US appeals court has upheld a Louisiana law regulating the distribution of 340B-discounted drugs, marking a significant setback for AbbVie and AstraZeneca in their ongoing legal battles against state regulations of the federal 340B program. This ruling reinforces the authority of states to impose restrictions on how these discounted medications are dispensed, a move that could reshape the operational landscape for pharmaceutical companies engaged in the 340B program.
The implications of this decision extend beyond Louisiana, as it sets a precedent that may embolden other states to enact similar regulations, potentially complicating the compliance landscape for drug manufacturers. As the pharmaceutical industry grapples with increasing scrutiny over drug pricing and distribution practices, this ruling underscores the need for companies to adapt their strategies to navigate the evolving regulatory environment effectively.
Open the full market picture for your next decision →
